title: [Prostaplant treatment of benign prostatic hyperplasia].
abstract: 80 patients aged 48 to 91 years with verified benign prostatic hyperplasia (BPH) stage I and II, having contraindications to surgery, received prostaplant, extract of Sabal serrulata palm fluit, in a dose 320 mg once a day. The treatment resulted in improvement of subjective and objective parameters (the total IPSS score improved by 32.3%, quality of life by 36.4%; maximal urine flow rate by 27.4%, respectively). Residual urine volume reduced in patients of group I by 26.8%, in patients of group II by 25.5%. The drug tolerance was good. 3 patients failed treatment. Good and satisfactory effects were achieved in 69 and 8 patients, respectively. Therefore, prostaplant is effective in BPH.
authors.forename: A A
authors.initials: AA
authors.lastname: Medvedev
authors.forename: L A
authors.initials: LA
authors.lastname: Siniakova
authors.forename: A V
authors.initials: AV
authors.lastname: Zaĭtsev
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005227:Fatty Acids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010840:Phytosterols / Q000627:therapeutic use*; D010936:Plant Extracts / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016896:Treatment Outcome; D014463:Ultrasonography; D014563:Urodynamics
chemical_list: D004791:Enzyme Inhibitors; D005227:Fatty Acids; C099102:IDS 89 Sabal serrulata extract; D010840:Phytosterols; D010936:Plant Extracts